Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection.

Strict adherence to the prescribed drug regimen is one of the most important predictors of success in the antiretroviral therapy of HIV infection. Ideally, patients should learn to optimise their drug adherence before they start antiviral therapy. This study evaluated the predictive role of adherence during the first four weeks of treatment for mid-term treatment outcome. Adherence was evaluated using electronic dosing systems during the first 25 days of therapy in 66 drug-naïve patients starting a new antiretroviral therapy. Treatment outcome (HIV-RNA suppression) was evaluated at week 24 of treatment. Good adherence (>95%doses taken) was associated with better rates of viral suppression (77% vs. 44% Patients with HIV-RNA below 50 copies/ml). Specific education programmes targeted at the achievement of optimal adherence during the first few weeks of therapy might result in better treatment results.

[1]  R. Weber,et al.  Is unsafe sexual behaviour increasing among HIV-infected individuals? , 2004, AIDS.

[2]  D. Paterson,et al.  Measurement of Adherence to Antiretroviral Medications , 2002, Journal of acquired immune deficiency syndromes.

[3]  I. Frank.  Once‐Daily HAART: Toward a New Treatment Paradigm , 2002, Journal of acquired immune deficiency syndromes.

[4]  D. Vlahov,et al.  A PROSPECTIVE STUDY OF ADHERENCE AND VIRAL LOAD IN A LARGE MULTI-CENTER COHORT OF HIV-INFECTED WOMEN , 2002, AIDS.

[5]  Joan A. Caylà,et al.  Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. , 2002 .

[6]  M. Chesney,et al.  The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Marilyn M. Wagener,et al.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .

[8]  C. Fraser,et al.  Quantification of intrinsic residual viral replication in treated HIV-infected patients , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  V. Stone,et al.  Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[11]  F. Hecht,et al.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.

[12]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[13]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[14]  A. Telenti,et al.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.

[15]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.